This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
The category of type 0 biomarkers refers to pre-existing factors that influence disease susceptibility, outcome or therapeutic response (efficacy or toxicity) (Downing 2000). These markers may be genetic or acquired during life (e.g. viral infection, mutations in cancer) and constitute risk factors for disease. They equally form the basis of animal disease models, e.g. Zucker diabetic rats. The completion of the human genome and ongoing identification of the genetic polymorphisms and mutations within the germ line and cancer tissues has confirmed the previously unidentified existence of many patient subsets (Bertucci 2003). Consequently target selection for drug discovery has become more complex and the diagnostic challenges of personalised medicine and acquisition of human tissue banks from ethical and consented sources, compliant with the UK Human Tissue Act 2004, are now a priority for drug discovery. Personalised medicine is also a challenge for the commercial viability of niche new medical entities (NMEs) (Ross 2003, Lesko 2004). If clinical trial recruitment can be selectively based on patient subsets expressing the drug target, a better efficacy response could be anticipated, increasing the power of the clinical trial and attaining evidence for efficacy more rapidly as less patients need to be recruited. However smaller trials may impair the safety profiling of an NME. The technical means of screening hundreds of patient disease material samples (biofluids or tissue biopsies) is highly dependant on reagents (in particular antibodies) and tissue samples with reliable quality and provenance. The creation of tissue microarrays (TMAs) of clinical diagnostic biopsies and immunohistochemical staining for target protein expression allows for both the overall (brown) intensity of expression and heterogeneity of expression (e.g. cancer cell versus stroma, see Figure 1) and can enable early selection of target patient populations and individual cases.
However, as shown by the gefitinib experience in non-small cell lung cancer, additional complications of mutated targets influencing outcome will also modify the power of the trial (Simon 2004). Although having attracted less attention outside the arena of drug metabolism and pharmacokinetics (DMPK), patient genotype and target expression on bystander normal tissues is likely to help explain the heterogeneity in adverse events (AEs) in patients.
Type 1 efficacy biomarkers
This category refers to early events in disease progression, toxic changes or pharmacological events. As such it is of particular interest in preclinical disease models, toxicology and clinical pharmacology. The advent of the FDA Critical Path exploratory IND (http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html) and Fast Track (http://www.fda.gov/cber/gdlns/fsttrk.pdf) and the EMEA New Safe Medicines Faster programmes has revitalised the search for new early and specific type 1 biomarkers as a means to expedite early clinical drug development. To deliver early readouts of pharmacological activity, clinical pharmacologists base decision points as follows:
The other key requirement is to establish a pharmacokinetic:pharmacodynamic (PK:PD, biomarker based) relationship to assist with dose selection in normal volunteers and patients.
Generation of comprehensive adsorption, distribution, metabolism and excretion profiles in man has traditionally required the use of radiolabelled compounds and the regulatory safety package for such compounds. The advent of accelerator mass spectrometry (AMS) has permitted the early administration of trace (sub-pharmacological) doses of NMEs to man at microdoses of radioactivity not requiring lengthy radiobiological safety studies. Recent results from the CREAM programme have confirmed in a majority of cases that microdosing kinetic data are meaningful for PK at therapeutic exposures.
Type 1 safety biomarkers
Clinical adverse events and mortality related to drug treatment continues to be a major concern and the FDA has indicated that 1,500 plus subjects are needed to adequately define a drug’s safety profile prior to NDA submission. During clinical drug development, around 40% of the drug development attrition of NMEs is related to safety (20% clinical AEs, 20% preclinical toxicology) compared to 22% failing because of lack of efficacy. Biomarkers for toxicity in animals and man therefore merit greater attention.
Toxicity biomarkers should be;
Early so that onset during dose escalation in early clinical trials can allow dosing to be reduced or stopped before clinically significant AEs occur.
Specific so that the target organ indicated is accurate and erroneous signals from unrelated organs do not interfere with toxicity identification.
Sensitive so that low doses causing toxicity can be detected so that high dose potentially irreversible injury is not caused.
Unfortunately, most clinical biomarker work has focussed on efficacy and drug metabolism and pharmacokinetic factors and there are many clinical target organ toxicities that either cannot be monitored, or fail to meet the three criteria above. Of particular concern are toxicities affecting target organs where component cells are terminally differentiated in adulthood, e.g. neurons, cardiomyocytes. Human patient AE rates may be insufficient for detection prior to marketing approval and withdrawal of marketed products can have a huge impact on patients, clinicians and pharmaceutical companies, e.g. coxibs. Human genetics have been associated with susceptibility to xenobiotic toxicity and carcinogenicity (Norppa, 2003) for many years and now with the advent of cytochrome P450 CYP polymorphism testing reagents, it should be feasible to exclude poor or atypical metabolisers from specific drug treatments.
Toxicity biomarkers used for standard safety screening in toxicology and during clinical development have changed little in recent decades. For example ‘liver function tests’ such as ALAT measure leakage of enzyme from hepatocytes rather than provide actual data on organ function. Safety biomarkers may be derived from hypothesis driven (‘biased’) approaches if a mechanism basis is known (Expert Working Group, 2005) but if mechanisms are unknown, more holistic ‘omics (‘fishing’) approaches may be needed to generate mechanism and biomarker data. More recent application of metabonomics (Nicholson 2002, Gavaghan, 2000) and transcriptomics can generation vast datasets requiring complex pattern recognition algorithms to provide a toxicity ‘fingerprint’. No single analyte to put into high throughput assays may emerge as a specific biomarker and altered multifactorial patterns may be needed. The problems of data reduction from meta-analysis of combined ‘omics technologies emerging from systems biology approaches becomes even more abstract although biological plausibility can be increased by pathway mapping to rationalise datasets (Wetmore 2004).
Type 2 biomarkers and surrogate biomarkers
This category refers to later clinical responses, either therapeutic or adverse events and offers the potential for early NDA approval in the basis of a validated surrogate biomarker approval in serious or life threatening disease. These biomarkers can become surrogates for traditional clinical outcomes based on morbidity or mortality. Where the time to end-point is protracted, e.g. cancer survival, surrogate biomarkers become attractive but demonstration that the surrogate is inextricably linked to survival can be challenging (Schatzkin 2001). This can however allow early Critical Path registration in serious or life threatening disease indications.
Approaches to discovery of new biomarkers
Biomarkers have been discovered during the course of many years as part of the laboratory investigation of clinical disease. Historically, clinical pathologists have found diagnostic biomarkers through a process of serendipity and hypothesis testing. One issue with the adaptation of these traditional biomarkers of disease is that they have been developed for clinical diagnosis where disease is already established and specificity has been paramount. Early onset and high sensitivity have been secondary considerations. They have been designed for target organ specificity rather than mechanism based. Also mechanism-based biomarkers can be disadvantageous in safety screening as opposed to hypothesis testing studies. Independence of mechanism is an advantage in many regards but will be less indicative of early adverse pharmacological or physiological consequences of drug treatment.
Proteomics traditionally has relied on the low throughput 2-D gel electrophoresis technology and can resolve not only individual proteins but also their post-translationally modified forms (Kennedy 2002, Man 2002, Srinivas 2002) and picking out single spots for tryptic digestion and sequencing by MALDI profiles permits both isolation and identification of novel biomarkers.
SELDI (Reddy 2003) provides a high throughput low sample requirement screening tool based on mass spectrometry proteomics (Petricoin 2002). Applications in preclinical toxicology are also numerous. For example, in a rat gentamycin nephrotoxicity model comparing control (top trace) and two treated (lower 2 traces) urine samples showed a spectrum of protein changes with each molecular weight altered expression being indicated by the green bars (Figure 2).
Once protein peaks or spots of interest have been identified as being of interest as a potential biomarker, it will be necessary to establish a more high throughput assay so the many experimental variables can be quantified. This is usually dependant on the development of an ELISA or similar assay. For example the protein or peptide of interest needs to be purified and sequences and antibodies generated if not commercially available, using the following schema (Figure 3):
Functional biomarkers e.g. PET (Frank 2003) reflecting target organ metabolic capability as opposed to downstream consequence such as cell leakage, death, proliferation or neoplasia provide a greater challenge than measurement circulating or excreted leakage markers in biofluids or cells. Imaging technologies have improved significantly in terms of speed, cost and resolution.
Structural biomarkers based in imaging can quantified, e.g. by volumetric measurement of articular cartilage, with great accuracy using MRI (Gandy 2005). Classical markers such as radiography have been developed into dual spectrum methods to quantify bone mineral density in trials of anti-osteoporosis agents
Novel biomarker validation ICCVAM process
The identification of novel biomarkers of efficacy or safety requires a lengthy process if they are to gain acceptance by regulations and the scientific and clinical community (Ransohoff 2004). In the US, the interagency ICCVAM organisation (http://iccvam.niehs.nih.gov/) recommends a number of stages for validation as follows:
Biomarker deliverables
The following applications of type 0, 1 or 2 biomarkers to preclinical and clinical drug development should ensue;
a) Target localisation to specific cell populations involved in toxicity or disease pathogenesis
b) Target expression in potential toxicity target organs
c) Ensuring animal disease model is representative of pathogenesis in man
d) Refinement of pharmacodynamic endpoints
e) Biomarkers of efficacy can give earlier read-out of activity in animal models and identify human polymorphisms
f) Biomarkers of toxicity validated in animals can permit judicious dose escalation in man and early withdrawal if AEs occur
g) Biomarkers of toxicity can also help mechanism of action studies and species difference rationales expected by regulators and clinicians
Conclusions
Biomarkers are evolving rapidly and new ones are being discovered for both efficacy and safety applications. It is important that these are selected and validated in the appropriate settings and that information sharing permits regulatory and scientific acceptance of novel markers.
References
Bertucci, F, Viens, P et al (2003) DNA arrays in clinical oncology; promises and challenges. Lab Invest 83;305-316
Downing, G L (Ed) (2000) Biomarkers and surrogate endpoints; clinical research and applications. Elsevier. ISBN 0-444-50316-1
Expert working group on drug-induced vascular injury (2005) Drug induced vascular injury – a quest for biomarkers. Toxicol Appl Pharm 203;62-87.
Frank, R and Hargreaves, R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Disc 2;566-580
Gandy, S J, Brett, A D, Dieppe, P A, Keen, MC, Maciewicz, R A, Taylor, C J, Waterton, J C and Watt, I.(2005) Measurement of cartilage volumes in rheumatoid arthritis using MRI. Br J Radiol 78; 39-45.
Gavaghan, CL, Holmes, E.et al (2000) An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences; application to the C57BL10J and Alpk:ApfCD mouse. FEBS Letters 24251;1-6
Kennedy, S (2002) The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7;269-290.
Lesko, L J and Woodcock, J (2004) Translation of pharmacogenomics and pharmacogenetics; a regulatory perspective. Nat Rev Drug Discov 3;763-769.
Man, W J, Whire, I R et al (2002) Protein expression analysis of drug mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2;1577-1585.
Nicholson, J.K., Connelly, J. et al (Feb 2002) Metabonomics: a platform for studying drug toxicity and gene function. Nature Reviews: Drug Discovery 1;153-161.
Norppa,H (2003) genetic susceptibility, biomarker responses and cancer. Mutat Res 544;339-348.
Petricoin,E F , Zoon,Z C et al (Sept 2002) Clinical proteomics: translating benchside promise into bedside reality. Natures Rev Drug Discovery 1;683-695.
Ransohoff, D F (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309-314.
Reddy, G and Dalmasso E A (2003) SELDI ProteinChip array technology: protein based predictive medicine and drug discovery applications. J Biomed Biotech 4:237-241.
Ross, J S and Ginsberg, G S. (2003) The integration of molecular diagnostics with therapeutics. Amer J Clin Pathol 11;26.
Schatzkin, A and Gail, M (2001) The promise and perils of surrogate endpoints in cancer research. Nat Rev Cancer 2:1-9.
Simon, R and Maitournam, A (2004) Evaluating the efficiency of targeted designs for randomised clinical trials. Clin Cancer Res 10; 6759-6763
Srinivas, P.R., Verma, M.et al (2002) Proteomics in cancer biomarker discovery. Clin Chemistry 48;1160-1169.
Wetmore, B A and Merrick, B A (2004) Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol 32;619-642.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.